Prescription Drugs

Refine your results

Filters

Content type

Mission

Displaying 21 - 40 of 302

Press Release

FTC Reaches Proposed Settlement with Surescripts in Illegal Monopolization Case

Date

July 27, 2023

The Federal Trade Commission filed a proposed order that would prohibit health information technology company Surescripts from engaging in exclusionary conduct and executing or enforcing non-compete...

Cases and Proceedings

Commissioner Statements

Statement of Chair Lina M. Khan Regarding the Policy Statement Concerning Reliance on Prior PBM-Related Advocacy Statements and Reports

Date

July 20, 2023

Lina M. Khan, Chair

Statement of Chair Lina M. Khan Regarding the Policy Statement Concerning Reliance on Prior PBM-Related Advocacy Statements and Reports (145.49 KB)

Press Release

FTC Votes to Issue Statement Withdrawing Prior Pharmacy Benefit Manager Advocacy

Date

July 20, 2023

The Federal Trade Commission voted to issue a statement cautioning against reliance on prior advocacy statements and studies related to pharmacy benefit mangers (PBMs) that no longer reflect current...

Cases and Proceedings

Commissioner Statements

Statement of Commissioner Rebecca Kelly Slaughter Regarding the Health Breach Notification Rule and the Biometric Policy Statement as Prepared for Delivery

Date

July 20, 2023

Rebecca Kelly Slaughter, Commissioner

Statement of Commissioner Rebecca Kelly Slaughter Regarding the Health Breach Notification Rule and the Biometric Policy Statement as Prepared for Delivery (151.49 KB)

Press Release

FTC Announces Tentative Agenda for July 20 Open Commission Meeting

Date

July 13, 2023

Today, Federal Trade Commission Chair Lina M. Khan announced that an open meeting of the Commission will be held virtually on Thursday, July 20, 2023. The open meeting will commence at 11am ET and...

Press Release

FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market

Date

June 20, 2023

The Federal Trade Commission filed a friend-of-the-court (amicus) brief in the U.S. Court of Appeals for the Second Circuit, clarifying the legal standards that apply in certain antitrust cases...

Press Release

FTC Further Expands Inquiry Into Prescription Drug Middlemen Industry Practices

Date

June 8, 2023

As part of its ongoing study on pharmacy benefit managers (PBMs) and their impact on the accessibility and affordability of prescription drugs, the Federal Trade Commission has issued a compulsory...

Press Release

FTC, DOJ Issue Summary on Joint Pharmaceutical Merger Analysis Workshop

Date

June 1, 2023

The Federal Trade Commission and the U.S. Department of Justice, Antitrust Division released a summary of a two-day workshop that explored new approaches to enforcement of the antitrust laws in the...

Press Release

FTC Deepens Inquiry into Prescription Drug Middlemen

Date

May 17, 2023

As part of its ongoing inquiry into pharmacy benefit managers (PBMs) and their impact on the accessibility and affordability of prescription drugs, the Federal Trade Commission has issued compulsory...

Cases and Proceedings

Amgen Inc. and Horizon Therapeutics plc, FTC v.

Type of Action

Federal

Last Updated

May 16, 2023

FTC Matter/File Number

231 0037

Case Status

Pending

Amicus Briefs

Sage Chemical, Inc. et al. v. Supernus Pharmaceuticals, Inc. et al.

Date

March 21, 2023

Federal Court

District of Delaware

The Federal Trade Commission filed an amicus brief with the U.S. District Court for the District of Delaware in the case of Sage Chemical, Inc. et al. v. Supernus Pharmaceuticals, Inc. et al. The...

Federal Trade Commission's Brief as Amicus Curiae (370.11 KB)

Press Release

FTC Asks Federal Court to Hold ‘Pharma Bro’ Martin Shkreli in Contempt

Date

January 20, 2023

The Federal Trade Commission asked a federal judge to hold “Pharma Bro” Martin Shkreli in contempt for failing to provide the FTC with information needed to determine whether he is violating a...

Amicus Briefs

Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

Date

November 10, 2022

Citation Number

1:21-cv-00691

Federal Court

District of Delaware

The Federal Trade Commission filed an amicus brief with the U.S. District Court for the District of Delaware in the case of Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals. The Brief highlights the...

Federal Trade Commission's Brief as Amicus Curiae (460.14 KB)

Federal Register Notice

HISA Anti-Doping and Medication Control Rule

Date

October 28, 2022

Report

Federal Trade Commission Report on Pharmaceutical Product Hopping

Date

October 21, 2022

Commission Report on Pharmaceutical Product Hopping (222.86 KB)

Public Statement

Remarks of Chair Lina M. Khan at the American Economic Liberties Project and the National Community Pharmacists Association Event Titled How Pharmacy Benefit Managers Impact Drug Prices, Communities, and Patients

Date

June 22, 2022

Remarks of Chair Lina M. Khan at the American Economic Liberties Project and the National Community Pharmacists Association (171.55 KB)

Public Statement

Remarks of Chair Lina M. Khan Regarding Policy Statement on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products

Date

June 16, 2022

Remarks of Chair Lina M. Khan Regarding Policy Statement on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products (167.26 KB)

Cases and Proceedings

Commissioner Statements

Statement of Commissioner Rebecca Kelly Slaughter Regarding the Policy Statement of the Federal Trade Commission on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products

Date

June 16, 2022

Rebecca Kelly Slaughter, Commissioner

Matter Number

P221201

Statement of Commissioner Rebecca Kelly Slaughter Regarding the Policy Statement of the Commission on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Prices (155.17 KB)

Press Release

FTC to Ramp Up Enforcement Against Any Illegal Rebate Schemes, Bribes to Prescription Drug Middleman That Block Cheaper Drugs

Date

June 16, 2022

The Federal Trade Commission announced that it will ramp up enforcement against any illegal bribes and rebate schemes that block patients’ access to competing lower-cost drugs. The enforcement policy...

Policy Statements

Policy Statement of the Federal Trade Commission on Rebates and Fees in Exchange for Excluding Lower Cost Drug Products

Date

June 16, 2022

Matter Number

P221201

Policy Statement of the Federal Trade Commission on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products (258.92 KB)

Displaying 21 - 40 of 302

Search or browse the Legal Library

Take action

Competition Matters Blog

Search or browse the Legal Library

Take action

Feature

Vision and Priorities

Technology Blog

Advice and Guidance

Take action

Servicemembers: Your tool for financial readiness

Get consumer protection basics, plain and simple

Learn how the FTC protects free enterprise and consumers

Looking for competition guidance?

Latest News

Upcoming Event

Follow us on social media

Feature

Latest Data Visualization

Featured

Meet the Chair

Tag: Prescription Drugs

Refine your results

Refine your results

Search or browse
the Legal Library

Search or browse
the Legal Library

Servicemembers:
Your tool for financial readiness